Home / Stock ratings / ZBH
Stock rating · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zimmer Biomet Holdings, Inc. (ZBH) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Zimmer Biomet Holdings, Inc. 71 out of 100 (Highest Conviction). Its highest factor scores are valuation and catalyst setup at 79, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-06ZBH · composite score
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants along with supplies and surgical equipment for orthopedic surgery. Following its acquisitions of Centerpulse (2003) and Biomet (2015), it holds the leading reconstructive market share in the US, Europe, and Japan. About two-thirds of revenue comes from large joints and about a fourth from extremities, trauma, sports medicine, and related products. It spun off its dental and spine businesses in 2022.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why ZBH scores 71/100
ZBH's 8 factor scores run from 50 to 79, and 4 of them sit above its composite of 71. Here is how ZBH breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 9.9x, earnings growth accelerating
- PEG ratio 0.58 (< 1 = undervalued)
- FCF yield 6.3%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 70%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Earnings in 29 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 29 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How ZBH compares
As of October 6, 2026, Zimmer Biomet Holdings, Inc. ranks 1st of the 3 companies with a MELANY rating page in its SEC industry group (Orthopedic, Prosthetic & Surgical Appliances & Supplies), where the average score is 66.
Key risks for ZBH
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Zimmer Biomet Holdings, Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds ZBH's momentum and catalyst factors above.
ZBH trade plan (Pro)
MELANY has a full position plan for Zimmer Biomet Holdings, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates ZBH
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Zimmer Biomet Holdings, Inc.'s 71/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ZBH
Is Zimmer Biomet Holdings, Inc. (ZBH) a buy?
As of 2026-10-06, MELANY rated Zimmer Biomet Holdings, Inc. Highest Conviction with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Zimmer Biomet Holdings, Inc.'s MELANY score?
Zimmer Biomet Holdings, Inc. (ZBH) has a MELANY composite score of 71/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the ZBH stock rating calculated?
MELANY scores ZBH from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Zimmer Biomet Holdings, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Zimmer Biomet Holdings, Inc. (ZBH) Highest Conviction with a composite of 71/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ZBH stock price forecast?
MELANY does not publish price targets or forecasts for ZBH. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for Zimmer Biomet Holdings, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ZBH stock overvalued or undervalued?
MELANY's valuation factor currently reads 79/100 for Zimmer Biomet Holdings, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ZBH's read.
What price should I buy ZBH at?
Rather than chasing the current price, MELANY computes a smart entry zone for ZBH: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying ZBH stock?
The top risks MELANY currently flags for Zimmer Biomet Holdings, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Zimmer Biomet Holdings, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 63/100 for Zimmer Biomet Holdings, Inc., and earnings track record, at 76/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ZBH stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 58/100 for ZBH right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ZBH rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ZBH continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, ZBH included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.